Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY23 results · Apr–Jun 2022
Alivus Life Sciences reported revenue from operations of ₹489.87 crore (down 6.7% from Q1 FY22) and net profit of ₹108.73 crore (up 7.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 489.87 | 524.90 | −6.7% | 514.06 | −4.7% |
| Other income | 9.49 | 3.99 | +138.2% | 5.09 | +86.3% |
| Total income | 499.36 | 528.88 | −5.6% | 519.15 | −3.8% |
| Profit before tax | 146.25 | 134.97 | +8.4% | 137.63 | +6.3% |
| Net profit for the period | 108.73 | 100.91 | +7.7% | 98.90 | +9.9% |
| EPS, basic (₹) | 8.87 | 9.36 | not comparable | 8.07 | +9.9% |
| Net margin (%) | 22.2 | 19.2 | 19.2 |
Standalone
- Filed with BSE
- 08 Aug 2022, 10:50 IST
- Board meeting
- 04 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE